US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
German family-owned drugmaker Grünenthal Group today announced that its supervisory board has named Gabriel Baertschi to become Grünenthal’s new chief executive as of October 1, 2016. 7 June 2016
Germany’s Merck (MRK: DE) and US pharma giant Pfizer (NYSE: PFE) plan to file for accelerated approval of avelumab for the treatment of patients with metastatic merkel cell carcinoma (MCC), it has been revealed. 6 June 2016
Embattled drug company Valeant has named Tyco International executive Sam Eldessouky as corporate controller and a senior vice president as it tries rebuild its reputation after a string of controversies. 27 May 2016
US biotech Gilead Sciences has added two names to its senior leadership team, with Kevin Young taking on the chief operating officer role and Martin Silverstein becoming executive vice president for strategy. 25 May 2016
US drugmaker Ariad Pharmaceuticals has appointed Jennifer Herron as executive vice president, chief commercial officer, effective May 31, 2016. 25 May 2016
UK biotech Silence Therapeutics has announced a number of changes to its management as it positions itself as a leading RNA technology company. 25 May 2016
Olivier Brandicourt, chief executive of French pharma major Sanofi, announced today a number of changes to the company's executive committee. 23 May 2016
UK-based Proteome Sciences has said that Jeremy Haigh will be joining its board of directors as chief executive in June (subject to regulatory approval). 18 May 2016
Novartis late yesterday announced major changes to focus its Pharmaceuticals Division by creating two business units reporting to the chief executive: Novartis Pharmaceuticals and Novartis Oncology. 18 May 2016
Japanese pharma major Takeda Pharmaceutical has appointed James Kehoe as its new chief financial officer (CFO), hailing his ‘passion for transforming large organizations’ as key to the company’s growth ambitions. 16 May 2016
Japanese drug major Astellas has appointed Rodrigo Fernandez executive director, international business, with responsibility for managing business in Latin America outside of Brazil. 29 April 2016
Ireland-based Perrigo has announced that Sharon Kochan will lead the expansion of the company’s branded consumer healthcare (BCH) segment. 28 April 2016
US biotech major Biogen has lured Michael Ehlers, a senior vice president at pharma giant Pfizer, as its executive vice president, Research and Development. 27 April 2016
Troubled Valeant Pharmaceuticals has named Joseph Papa as its new chief executive, calling him an appointment with “an ethical approach.” 25 April 2016
Maya Martinez-Davis has been appointed as global head of oncology of the biopharma business of German pharma giant Merck KGaA, it was announced on Thursday. 14 April 2016